Everest Medicines' Two Drugs Added to China's 2026 Reimbursement List

MT Newswires Live11-16

Everest Medicines (HKG:1952) said China's 2026 National Reimbursement Drug List will include its ulcerative colitis drug Velsipity and antibiotic Xerava for the first time.

Velsipity, an oral treatment for adults with moderately to severely active ulcerative colitis, was approved by China's National Medical Products Administration in February 2026, according to a Monday Hong Kong bourse filing. Xerava, an intravenous antibiotic for complicated intra-abdominal infections in adults, received Chinese approval in March 2023 and was launched in July that year.

The updated reimbursement list will take effect on Jan. 1, 2027. The company's kidney disease drug Nefecon will also remain on the list.

Shares of the company rose over 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment